Home > Insider Trading > Filing (0001209191-10-036694)

Filing Details

Accession Number:: 0001209191-10-036694
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-07-01 13:00:00
Reporting Period:: 2010-06-30

Filing Date:: 2010-07-01
Accepted Time:: 2010-07-01 19:58:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1061027	Sunesis Pharmaceuticals Inc	SNSS	Pharmaceutical Preparations (2834)	943295878

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1288452	Bay City Capital Llc	750 Battery Street Suite 400 San Francisco CA 94111	No	No	Yes	No
1401826	Bay City Capital Fund V, L.p.	750 Battery Street Suite 400 San Francisco CA 94111	No	No	Yes	No
1409813	Bay City Capital Fund V Co-Investment Fund Lp	750 Battery Street Suite 400 San Francisco CA 94111	No	No	Yes	No
1461543	Bay City Capital Management V Llc	750 Battery Street Suite 400 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-06-30	9,808,090	$0.00	9,808,090	No	4	C	Direct
Common Stock	Acquisiton	2010-06-30	23,378,934	$0.28	33,187,024	No	4	P	Direct
Common Stock	Acquisiton	2010-06-30	186,900	$0.00	186,900	No	4	C	Direct
Common Stock	Acquisiton	2010-06-30	445,516	$0.28	632,416	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	P	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2010-06-30	980,809	$2.20	9,808,090	$0.00
Common Stock	Series A Preferred Stock	Disposition	2010-06-30	18,690	$2.20	186,900	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2010-06-30		No	4	C	Direct
0	2010-06-30		No	4	C	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	9,091	Direct

Footnotes

Each one (1) share of Series A Preferred Stock was converted into ten (10) shares of Common Stock upon the Issuer's common equity closing (as defined in the applicable Certificate of Designation).
Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purpose of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V.
Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaim beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.
Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaim beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.
BCC is the sole owner of these shares.
Not applicable.